6 results match your criteria: "Robert Koch Medical Center[Affiliation]"
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Eur J Heart Fail
October 2022
University of Washington Heart Institute, Seattle, WA, USA.
Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.
Methods And Results: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes).
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
Cardiovasc Diabetol
August 2022
St. John's Research Institute, St. John's National Academy of Health Sciences, Bangalore, India.
Background: The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler way of assessing risk.
Methods: 9115 of 9901 Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) participants with both an ACR and eGFR at baseline were included in this post hoc epidemiologic analysis.
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.
J Clin Endocrinol Metab
July 2022
Robert Koch Medical Center, Sofia, Bulgaria.
Article Synopsis
- - The study examined the link between low cognitive scores, measured by the MoCA and DSST, and the risk of cardiovascular events among participants in the REWIND trial, focusing on those with significant cognitive impairment (SCI).
- - Out of 8,772 participants, 905 (10.3%) with SCI experienced a higher incidence of major adverse cardiovascular events (MACE) and a greater risk of stroke or death compared to those without (89.7%).
- - Stronger associations were observed for a composite measure (SCI-GM), which remained significant even after adjusting for various risk factors, indicating that standardized cognitive impairment is a strong predictor of cardiovascular risks in individuals with type 2 diabetes.
Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial.
Methods: REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries.
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Lancet Diabetes Endocrinol
February 2020
Robert Koch Medical Center, Sofia, Bulgaria.
Background: Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial.
Methods: REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries.
The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.
View Article and Find Full Text PDF